Drugs / Lu-177 PSMA-617
Lu-177 PSMA-617
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03828838 | Jul 2018 → Nov 2019 | prostate neoplasm | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06798558 | Mar 2025 → Mar 2029 expected | prostate adenocarcinoma | Hackensack Meridian Health | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06959433 | May 2026 → Feb 2028 expected | kidney cancer | Ankara University | Not yet recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lu-177 PSMA-617 | “2 cycles of Lu-177-PSMA-617 (PluvictoⓇ) administered at 6-week intervals before prostatectomy in patients with high risk localized prostate cancer.” NCT06798558 ↗ |
| Known as | [177Lu]Lu-PSMA-617 | “BACKGROUND: Dosimetry in [177Lu]Lu-PSMA therapy is a valuable tool to assess treatment efficacy and toxicity. This study aims to develop a clinically implementable protocol to...” PMID 36692682 ↗ Jan 2023 |
| Known as | Lu-177 PSMA | “Two cycles of Lu-177 PSMA (3GBq and 3-6 GBq)” NCT03828838 ↗ |
| Known as | Lutetium-177-PSMA-617 | “Lutetium-177-PSMA-617 in Low-Volume Hormone-Sensitive Metastatic Prostate Cancer: A Prospective Pilot Study.” PMID 33883176 ↗ Apr 2021 |
| Known as | PluvictoⓇ | “2 cycles of Lu-177-PSMA-617 (PluvictoⓇ) administered at 6-week intervals before prostatectomy in patients with high risk localized prostate cancer.” NCT06798558 ↗ |
| Modality | Other / unclassified | “radionuclide treatment option” NCT06959433 ↗ |